News / Taiwan / economic_daily
OBI Pharma's Klebsiella Pneumoniae Vaccine Shows Positive Phase 1 Clinical Results
Health Technology · Biotechnology · economic_daily · 2026-10-22
6586
OBI Pharma announced promising interim Phase 1 clinical trial results for its CHO V08 vaccine, demonstrating strong safety profiles and immune responses.
What Happened
Clinical Trial Success: OBI Pharma's CHO V08 vaccine for Klebsiella pneumoniae has reported positive interim results from its first-in-human Phase 1 clinical trial. The data indicates a favorable safety profile and robust immune response, with 88% and 86% of subjects showing a four-fold increase in K1 and K2 bactericidal activity, respectively.
Safety Profile: The study involved 41 healthy adults and demonstrated good overall tolerability. Reported adverse events were mild, such as injection site pain and fatigue, with no serious adverse events or safety concerns observed during the trial period.
International Interest: The clinical findings were presented at the World Vaccine Congress in Europe, drawing positive feedback from global experts and interest from major international vaccine developers. The company is currently pursuing international partnerships and licensing opportunities to support further development.
Future Outlook: While the bactericidal activity results are encouraging, the company noted that further analysis is required to correlate these findings with clinical protection. Future efforts will focus on completing the Phase 1 follow-up and evaluating dosing schedules for subsequent clinical stages.